Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720788 | 0.84 | PTPN7 (0.42) | P2RX7 | |
| SCHEMBL2600033 | 0.78 | IDO1 (0.57) | IDO1PYCR1KDRP2RX7LMNA | |
| SCHEMBL12497617 | 0.76 | IDO1 (0.51) | IDO1PYCR1KDRP2RX7 | |
| SCHEMBL1720267 | 0.75 | TAAR1 (0.39) | IDO1LMNAMAOB | |
| SCHEMBL1720743 | 0.75 | IDO1 (0.58) | IDO1PYCR1KDRP2RX7LMNA | |
| SCHEMBL8824450 | 0.75 | SLC6A4 (0.50) | LMNAMAPT | |
| SCHEMBL4084168 | 0.75 | IDO1 (0.57) | IDO1PYCR1KDRP2RX7FAAH | |
| SCHEMBL1720925 | 0.74 | POLQ (0.45) | P2RX7KDM4EMAPT | |
| SCHEMBL564639 | 0.74 | RIPK1 (0.39) | LMNAMAOBMAPT | |
| SCHEMBL1719722 | 0.74 | HTR2A (0.46) | IDO1LMNAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730126-B1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7244728-B2 | Long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| EP-1730126-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092870-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1577306-A1 | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | ADRA1D, ADRB2, ADRA1A | IDO1 1541/4885PYCR1 1209/4885KDR 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.